Edward Nirenberg on Nostr: Today's ACIP meeting also featured a presentation from Merck regarding clesrovimab, ...

Today's ACIP meeting also featured a presentation from Merck regarding clesrovimab, an RSV monoclonal antibody targeting antigenic site IV (nirsevimab is site Ø and palivizumab is site II):
https://www.cdc.gov/acip/downloads/slides-2024-10-23-24/02-RSV-Mat-Peds-Sinha-508.pdf

I'll summarize...